FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143547042> ?p ?o ?g. }

• W2143547042 endingPage "1997" @default.
• W2143547042 startingPage "1995" @default.
• W2143547042 abstract "The risk of venous thromboembolism (VTE) is increased substantially in patients with malignant disease, most notably cancers of the pancreas, stomach, kidney, ovary, lung, and CNS, as well as certain hematologic malignancies. The risk of VTE is further increased in patients with cancer and certain demographic-, diseaseand treatment-related characteristics. Patients with major medical comorbidities such as infection, pulmonary disease, and renal failure are notably at increased risk. In addition to hospitalized patients with cancer and those in the perioperative period, patients receiving systemic therapies including chemotherapy, hormonal therapy, and certain targeted agents are at several-fold increased risk for VTE compared with the general population. Even certain supportive care measures, such as the use of the erythroidstimulating agents and blood transfusions, have been associated with an increased risk of VTE. The identification of several factors associated with cancerassociated VTE has led to the development of multivariable risk models for cancer-associated risk. A VTE risk model was developed on the basis of a prospective cohort of 2,701 ambulatory patients during their initial three to four cycles of chemotherapy for cancer, and was validated in a separate group of 1,365 patients using five readily available clinical and laboratory risk factors that were identified. On the basis of this model, points were assigned and patients were classified as low, intermediate, and high risk for VTE according to cancer type, severe obesity (body mass index 35 kg/m), elevations in pretreatment platelet count ( 350,000/ L) and leukocyte count ( 11,000/ L), and either anemia ( 10 g/dL) or erythroid-stimulating agent use. The risk score has now been validated by a number of independent investigators in the United States and Europe. In a prospective cohort of 819 patients with cancer, Ay et al observed a cumulative risk of VTE at 6 months that ranged from 1.5% to 17.7% (1.5%, score 0; 3.8%, score 1; 9.4%, score 2; and 17.7%, score 3). It should be noted that in both the original model-development population and the various validation studies, high-risk patients represent approximately 10% of ambulatory patients receiving cancer chemotherapy. Current guidelines from both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend an evaluation of VTE risk and encourage the use of a validated risk score in ambulatory patients receiving cancer chemotherapy. Patients with cancers of the pancreas and upper GI tract have recently received particular attention because of the apparent greater risk for VTE than in other cancer types. A retrospective observational study of ambulatory patients with common solid malignancies initiating cancer chemotherapy reported overall rates of VTE at 3.5 months and 1 year of 7.3% and 13.5%, respectively. The greatest risk of VTE was observed in patients with advanced pancreatic cancer (APC) and was determined to be 11.6% and 21.3% at 3.5 and 12 months, respectively. It may be noted that patients who developed VTE in this cohort experienced more than twice the risk of major bleeding and had approximately 50% greater health care expenditures than similar patients who did not develop VTE. Although the prognosis of most patients with APC is poor, those with VTE have a particularly poor survival. Although the role of anticoagulation is well supported in the treatment of established VTE and for prevention of VTE in hospitalized patients with cancer, the role of thromboprophylaxis in ambulatory patients has not been firmly established. Several randomized controlled trials (RCTs) of thromboprophylaxis in ambulatory patients with cancer have been published, including 11 that compared low–molecular weight heparins (LMWHs) with either placebo or no prophylaxis. A meta-analysis estimated an overall relative risk for symptomatic VTE across published trials of 0.47 (95% CI, 0.36 to 0.61; P .001) but generally low rates of VTE and an overall absolute reduction in VTE risk of only 2.8% (95% CI, 1.8% to 3.7%; P .001). The largest RCT of an LMWH for thromboprophylaxis in patients with solid malignancies demonstrated a hazard ratio for VTE of 0.36 (95% CI, 0.21 to 0.60; P .001) but observed absolute rates of VTE of only 3.4% and 1.2% among control and LMWH-treated patients, respectively. At the same time, the largest absolute rates of VTE were observed in trials of patients with APC. The long-awaited publication of CONKO-004 (Prospective Randomized Trial of Simultaneous Pancreatic Cancer treatment With Enoxaparin and Chemotherapy) that accompanies this article provides the opportunity to reconsider the risk of VTE in patients with JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 33 NUMBER 18 JUNE 2" @default.
• W2143547042 created "2016-06-24" @default.
• W2143547042 creator A5041299305 @default.
• W2143547042 creator A5073060840 @default.
• W2143547042 date "2015-06-20" @default.
• W2143547042 modified "2023-10-14" @default.
• W2143547042 title "When to Offer Thromboprophylaxis to Patients With Advanced Pancreatic Cancer: Shedding Light on the Path Forward" @default.
• W2143547042 cites W1506072545 @default.
• W2143547042 cites W1573083214 @default.
• W2143547042 cites W1589295587 @default.
• W2143547042 cites W164440564 @default.
• W2143547042 cites W1973509710 @default.
• W2143547042 cites W1995391277 @default.
• W2143547042 cites W1995828607 @default.
• W2143547042 cites W1996600303 @default.
• W2143547042 cites W2040800118 @default.
• W2143547042 cites W2041113507 @default.
• W2143547042 cites W2043133560 @default.
• W2143547042 cites W2054324054 @default.
• W2143547042 cites W2063853621 @default.
• W2143547042 cites W2107853873 @default.
• W2143547042 cites W2111885463 @default.
• W2143547042 cites W2129790170 @default.
• W2143547042 cites W2137283681 @default.
• W2143547042 cites W2149588262 @default.
• W2143547042 cites W2167494200 @default.
• W2143547042 cites W2172181565 @default.
• W2143547042 cites W2273563140 @default.
• W2143547042 cites W2490019007 @default.
• W2143547042 cites W2980266010 @default.
• W2143547042 cites W4247355438 @default.
• W2143547042 doi "https://doi.org/10.1200/jco.2015.61.4164" @default.
• W2143547042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25987699" @default.
• W2143547042 hasPublicationYear "2015" @default.
• W2143547042 type Work @default.
• W2143547042 sameAs 2143547042 @default.
• W2143547042 citedByCount "8" @default.
• W2143547042 countsByYear W21435470422016 @default.
• W2143547042 countsByYear W21435470422017 @default.
• W2143547042 countsByYear W21435470422019 @default.
• W2143547042 countsByYear W21435470422020 @default.
• W2143547042 countsByYear W21435470422022 @default.
• W2143547042 countsByYear W21435470422023 @default.
• W2143547042 crossrefType "journal-article" @default.
• W2143547042 hasAuthorship W2143547042A5041299305 @default.
• W2143547042 hasAuthorship W2143547042A5073060840 @default.
• W2143547042 hasBestOaLocation W21435470421 @default.
• W2143547042 hasConcept C121608353 @default.
• W2143547042 hasConcept C126322002 @default.
• W2143547042 hasConcept C143998085 @default.
• W2143547042 hasConcept C177713679 @default.
• W2143547042 hasConcept C199360897 @default.
• W2143547042 hasConcept C2777735758 @default.
• W2143547042 hasConcept C2780210213 @default.
• W2143547042 hasConcept C41008148 @default.
• W2143547042 hasConcept C71924100 @default.
• W2143547042 hasConceptScore W2143547042C121608353 @default.
• W2143547042 hasConceptScore W2143547042C126322002 @default.
• W2143547042 hasConceptScore W2143547042C143998085 @default.
• W2143547042 hasConceptScore W2143547042C177713679 @default.
• W2143547042 hasConceptScore W2143547042C199360897 @default.
• W2143547042 hasConceptScore W2143547042C2777735758 @default.
• W2143547042 hasConceptScore W2143547042C2780210213 @default.
• W2143547042 hasConceptScore W2143547042C41008148 @default.
• W2143547042 hasConceptScore W2143547042C71924100 @default.
• W2143547042 hasIssue "18" @default.
• W2143547042 hasLocation W21435470421 @default.
• W2143547042 hasLocation W21435470422 @default.
• W2143547042 hasOpenAccess W2143547042 @default.
• W2143547042 hasPrimaryLocation W21435470421 @default.
• W2143547042 hasRelatedWork W2091020218 @default.
• W2143547042 hasRelatedWork W2337729630 @default.
• W2143547042 hasRelatedWork W2365364931 @default.
• W2143547042 hasRelatedWork W2401514044 @default.
• W2143547042 hasRelatedWork W2418638721 @default.
• W2143547042 hasRelatedWork W2897496508 @default.
• W2143547042 hasRelatedWork W3103168443 @default.
• W2143547042 hasRelatedWork W3104966608 @default.
• W2143547042 hasRelatedWork W35632224 @default.
• W2143547042 hasRelatedWork W4252371801 @default.
• W2143547042 hasVolume "33" @default.
• W2143547042 isParatext "false" @default.
• W2143547042 isRetracted "false" @default.
• W2143547042 magId "2143547042" @default.
• W2143547042 workType "article" @default.